2017
Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014
Cleveland A, Johnson M, Gargano J, Park I, Griffin M, Niccolai L, Schafer S, Bennett N, Markowitz L, Unger E. Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014. Open Forum Infectious Diseases 2017, 4: s68-s69. PMCID: PMC5632134, DOI: 10.1093/ofid/ofx162.164.Peer-Reviewed Original ResearchNon-vaccine typesHPV typesCervical cancer screening methodsHPV typing resultsL1 consensus PCRHuman papillomavirus vaccinationPopulation-based surveillanceCancer screening methodsChi-square testCIN3 casesPapillomavirus vaccinationHPV typingMedian ageHPV-18Primary preventionCervical adenocarcinomaVaccine preventionPrecursor lesionsAIS casesCIN3Positive specimensHR typesCIN2Disease controlCell precursors
2011
O1-S02.06 Detection of cervical cancer precursors and associated HPV types in the USA: HPV-IMPACT preliminary results
Powell S, Hariri S, Steinau M, Bauer H, Bennett N, Bloch K, Schafer S, Niccolai L, Unger E, Markowitz L. O1-S02.06 Detection of cervical cancer precursors and associated HPV types in the USA: HPV-IMPACT preliminary results. Sexually Transmitted Infections 2011, 87: a25. DOI: 10.1136/sextrans-2011-050109.12.Peer-Reviewed Original ResearchHPV typesVaccine impactCervical intraepithelial neoplasia grade 2HPV vaccine impactMedian diagnosis ageCervical cancer precursorsMultiple HPV typesRoche Linear ArrayPreinvasive cervical lesionsProportion of lesionsHPV16 prevalenceHPV18 prevalenceCervical diseaseHPV DNAResidual lesionsDiagnosis ageCervical lesionsCancer precursorsDiagnostic blocksCase ascertainmentCIN2Grade 2Diagnosis rateFemales 18Type replacement